BeStock  
Stocks › Biotechnology › ALNY

Alnylam Pharmaceuticals ALNY

US equityMarket cap rank #931Biotechnology
$143.82 −$4.00 (-2.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $144.50 +0.47%
Open$148.35
Prev close$147.82
Day range$143.40 – $151.41
Volume2.33M
Market cap$19.26B
P/E (TTM)7.5
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings7.5x
CheapRich

Above its usual level · 79th percentile, 5-year average 19.6x

#401 of 2996 stocks by PE (1 = cheapest)

Price / book5.3x
CheapRich

Around its usual level · 40th percentile, 5-year average -502.0x

#4569 of 5338 stocks by PB (1 = cheapest)

Price / sales3.8x
CheapRich

Near the bottom of its 5-year range · 0th percentile, 5-year average 17.5x

#3726 of 5161 stocks by PS (1 = cheapest)

P/E over five years

-676x131x938x1,745xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$299.00
Price vs. fair value-51.9%Trading below the estimate
Star rating★★★★★
Economic moatNarrow
UncertaintyHigh
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 5.35 – -502.03 40% (cheaper than usual) #4569 of 5338 (1 = cheapest)
PE 7.48 20.24 19.64 79% (pricier than usual) #401 of 2996 (1 = cheapest)
PS 3.84 3.14 17.52 0% (cheaper than usual) #3726 of 5161 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on ALNY.

Sign in to join the discussion.

Scroll to Top